The Aurora kinases have been implicated in tumorigenesis and are important regulators of diverse cell cycle events, ranging from the entry into mitosis, centrosome function, mitotic spindle formation, chromosome biorientation and segregation, and cytokinesis. The recent identification of novel binding partners and key downstream effectors, together with new small-molecule inhibitors that display efficacy against tumours, heralds an upsurge of interest in these critical kinases. This review details new developments in the field and analyses the potential of Aurora kinases as anticancer targets.
Introduction
Many fundamental processes in cancer cells are regulated by protein phosphorylation: kinases regulate the cell's response to DNA damage, control DNA replication, regulate entry into, passage through and exit from mitosis, and ensure accurate chromosome segregation; they monitor nutrient availability and control cell growth pathways; and they regulate apoptosis and hence govern a cell's commitment either to live or to die.
In metazoans, there are three highly related Aurora kinases: Aurora A, B and C (reviewed in Andrews et al., 2003; Carmena and Earnshaw, 2003; Brown et al., 2004) . Despite their relatedness at the sequence level, the localization and functions of Aurora A and B are largely non-overlapping. Aurora A is localized at the centrosome from the time of centrosome duplication through to mitotic exit and regulates centrosome function. In contrast, Aurora B is localized to inner-centromeric chromatin from prophase until the metaphase-anaphase transition, whereupon it is relocalized to both the microtubules in the spindle midzone (and the cell cortex at the cleavage furrow) during telophase, ending up in the midbody throughout cytokinesis (see Figure 1 ; reviewed in Andrews et al., 2003; Carmena and Earnshaw, 2003; Meraldi et al., 2004) . Such behaviour marks out Aurora B as a canonical 'chromosome passenger' protein (Earnshaw and Cooke, 1991) , whose function is to ensure accurate chromosome segregation and timely cytokinesis. The approximate execution points of Aurora A and B are shown in Figure 2 . Aurora C's regulation and localization have remained obscure until recently (Li et al., 2004b; Sasai et al., 2004) and its real function is unknown.
With over protein 500 kinases in the human genome grouped into at least 20 structurally related families, the specificity of kinase inhibitors is a critical concern when administrated in therapy. However, the recognition that the selective inhibition of individual protein kinases is not only possible, but has therapeutic efficacy (as exemplified by the success of the Bcl-Abl kinase inhibitor, Gleevec, for the treatment of chronic myeloid leukemia) has led to a huge interest in the development of kinase inhibitors for cancer therapy.
Here, I review recent advances in our understanding of Aurora kinase function, critically assess how detailed knowledge of their function could be utilized in cancer therapy and go on to discuss whether the Aurora kinases are indeed suitable targets for therapeutic intervention.
Aurora A: cancer, centrosomes and the p53 connection
The human Aurora A gene, STK15, resides in a region of the genome (20q13.2) often amplified in certain cancers (Bar-Shira et al., 2002) . Aurora A overexpression occurs in a high proportion of breast, colorectal and gastric cancers (Tanaka et al., 1999; Sakakura et al., 2001; Goepfert et al., 2002; Gritsko et al., 2003; Moreno-Bueno et al., 2003; Fraizer et al., 2004; Jeng et al., 2004; Kamada et al., 2004; Tong et al., 2004) . While these data are largely correlative, more compelling was the observation that overexpression of a constitutively active mutant of Aurora A in rat1 cells led to neoplastic transformation, suggesting Aurora A is a bona fide oncogene (Bischoff et al., 1998) . However, in a recent report, controlled overexpression of Aurora A (STK6) in mice led to mitotic defects and mammary hyperplasia, but not malignant transformation . Aurora A was also recently shown to be a low-penetrance skin tumour-susceptibility gene, with an allelic variant (Ile31), frequently found amplified, whose presence was correlated with aneuploidy in human colon tumour cells, with the Ile31 allele transforming rat1 cells more potently than the more common Phe31 allele (Ewart-Toland et al., 2003) . A separate study also found a correlation between the Ile31 allele and the risk of breast carcinoma (Sun et al., 2004) . Aurora A overexpression can occur because of gene amplification, transcriptional induction or post-translational stabilization (Farruggio et al., 1999; Crane et al., 2004) . Indeed, in a recent study the p53-dependent loss of the tumour suppressor ubiquitin ligase, hCDC4 led to a stabilization of Aurora A levels (Mao et al., 2004) . Further evidence pointing to a complexity in the regulation of Aurora levels comes from a recent study in rats, where estrogen was shown to lead to increases in Aurora A protein and mRNA levels, centrosome amplification, chromosome instability and ultimately to breast cancer (Li et al., 2004a) . Aurora A's role in centrosome function and duplication is well established, yet still poorly understood (reviewed by Andrews et al., 2003; Meraldi et al., 2004) . Disruption of Aurora A function delocalizes several components of the centrosome. Aurora A phosphorylates and recruits microtubule-associated proteins such as the kinesin Eg5 (Giet et al., 1999) and the acidic coiled-coil protein, TACC (Giet et al., 2002; Bellanger and Gonczy, 2003; Conte et al., 2003) to the centrosome. Recently, the human Lats2 tumour-suppressor protein was also shown to be recruited to the centrosome via Aurora A-mediated phosphorlyation (Toji et al., 2004) .
Aurora A appears to control entry into mitosis by regulating either the association of the cell cycle machinery with centrosomes, or possibly even directly Dutertre et al., 2004) . Aurora A binds and phosphorylates the breast cancer-associated gene product, BRCA1, in vitro and in vivo and regulates its function (Ouchi et al., 2004) . Aurora A also regulates human telomerase reverse transcriptase mRNA levels through c-myc, in ovarian and breast epithelial carcinomas (Yang et al., 2004b) . The inter-relationship between all these pathways is, however, still obscure (see Figure 3) . Figure 1 Localization of Aurora A and B. Aurora A and B localize to different cellular structures. Aurora A localization to centrosome/spindle poles in metaphase and telophase (upper panels). Aurora B localization to the inner centromere from prometaphase to metaphase and then the spindle midzone microtubules in late anaphase/telophase (lower panels) and in the midbody during cytokinesis (not shown) Figure 2 Aurora kinase cell cycle execution points and substrates. Schematic diagram illustrating the known execution points and substrates of Aurora A and B across the cell cycle. The substrates phosphorylated in each phase of the cell cycle are color coded: orange circles indicate Aurora A substrates and green circles indicate Aurora B substrates. Ipl1p substrates are indicated as a double green and orange line Aurora A regulation is complex and involves the interplay between the small GTPase Ran and the spindle protein TPX2 as well as regulatory input from the type-1 protein phosphatase, PP1 (reviewed by Andrews et al., 2003; Gruss and Vernos, 2004) . Ran releases TPX2 from importins a and b allowing TPX2 to bind Aurora A, targeting it to spindle microtubules at the pole. TPX2 activates Aurora A activity by stimulating Aurora A autophosphorylation and by protecting it from the inhibitory action of PP1 (Eyers et al., 2003; Tsai et al., 2003) . The crystal structure of activated Aurora A in complex with a TPX2 fragment showed TPX2 binding is sufficient to allow autophosphorylation of the two activatory T-loop theonines, allowing Aurora A to adopt a conformation similar to the 'active' conformation of other Ser/Thr kinases (Bayliss et al., 2003) . This level of detailed knowledge is invaluable for the development of new Aurora A inhibitors that may specifically target the activation step.
Recently, an Aurora A-p53 connection has been revealed. Previously, parallels had been noticed between phenotypes associated with Aurora A gain-offunction mutations (or its overexpression) and those caused by p53 loss-of-function (Meraldi et al., 2002) . The activity and stability of p53 is governed by many post-translational modifications, most importantly, multisite phosphorylation. In an intriguing new development, Aurora A has been shown to phosphorylate Ser315 of p53, leading to its Mdm2-mediated destabilization . Aurora A RNAi led to a loss of Ser315 phosphorylation, p53 stabilization and a G 2 /M cell cycle arrest. In a separate study, phosphorylation of Ser215 of p53 abrogated p53's DNA-binding and transactivation function . To complicate matters further, p53 has been shown to block Aurora A activity, an effect overcome by TPX2 (Eyers and Maller, 2004) . How this web of interactions plays out in cells remains to be dissected. Aurora A may regulate p53 in vitro, but it is still unclear whether this occurs in vivo. Intriguingly, one report has shown Aurora A-mediated phosphorylation of CENP-A to be necessary to recruit Aurora B to the inner-centromere in prometaphase . This type of dependency between the two kinases and their substrates (summarized in Figure 3 ) will be important to verify in other cellular contexts.
Aurora B: regulator of kinetochore-microtubule attachment Cancer cells are often aneuploid, that is, they possess aberrant chromosome structure or number (Nowak et al., 2002; Rajagopalan et al., 2003) . Chromosome instability (CIN), one form of aneuploidy, is typified by the gain or loss of chromosomes and is linked to cancer progression (Rajagopalan and Lengauer, 2004) . To ensure each sister chromatid is faithfully segregated to the daughter cells in anaphase, sister kinetochores must become attached to microtubules emanating from opposite spindle poles in a process known as biorientation (reviewed by Andrews et al., 2003; see Figure 4 ). Errors in biorientation lead to CIN. Commonly encountered errors include merotelic attachments (one kinetochore attached to microtubules from both poles) and syntelic attachments (both kinetochores attached to microtubules from the same pole), as illustrated in Figure 4 . The cell's surveillance mechanisms (checkpoints; discussed below) that monitor the attachment and biorientation state of each chromosome give correction pathways sufficient time to ensure that all chromosomes are configured properly, and thereby segregated equally in anaphase. Aurora B plays a key role in this correction process.
Aurora B (Ipl1p) phosphorylates a number of kinetochore components in budding yeast and is essential for correcting errors in microtubule attachment (see Figures 2-4), thereby ensuring faithful chromosome segregation (Biggins et al., 1999; He et al., 2001; Kang et al., 2001; Cheeseman et al., 2002; Tanaka et al., 2002; Shang et al., 2003; Westermann et al., 2003) . In particular, Dam1p has been extensively characterized as an Ipl1p substrate acting downstream of Aurora B for microtubule attachment (Kang et al., 2001; Cheeseman et al., 2002; Shang et al., 2003) , although to date no clear Dam1p orthologues are known to exist in the genomes of higher eukaryotes. However, Aurora B's function appears to be conserved across evolution. In mammalian cells, the Aurora kinase inhibitor Hesperadin increased the incidence of mal-oriented chromosomes (Hauf et al., 2003) . Furthermore, another live cell study using a different Aurora kinase inhibitor (AKI) showed Aurora kinases to be required for correcting syntelic chromosomes (Lampson et al., 2004) . Understanding the molecular details of these processes and how Aurora B achieves biorientation is of prime importance for the future design of inhibitors, since on face value inhibiting this kinase would be predicted to enhance chromosome loss. How might Aurora B correct biorientation mistakes in human cells? Until recently, the only known Aurora B substrates in metazoans were histone H3, CENP-A, vimentin, desmin, GFAP, topoisomerase II, mgcRacGAP and myosin regulatory light chain, which have no clear link with biorientation (reviewed in Andrews et al., 2003) . Recently, however, a major advance came in three reports describing the identification of MCAK, a centromeric microtubuledestabilizing kinesin (reviewed by Ovechkina and Wordeman, 2003; Moore and Wordeman, 2004) , as an Aurora B substrate in vitro and in vivo, in human cells (Andrews et al., 2004) and Xenopus (Lan et al., 2004; Ohi et al., 2004) . MCAK is required for chromosome congression, biorientation, bipolar spindle formation and anaphase chromosome movement (see Moore and Wordeman, 2004) . Phosphorylation of MCAK by Aurora B inhibits MCAK's catalytic activity in vitro and in vivo (Andrews et al., 2004; Lan et al., 2004; Ohi et al., 2004) . More importantly, expression of phosphorylation-site mutants in cells increased the number of incorrectly attached chromosomes (lateral, monotelic and syntelic microtubule-kinetochore attachments), configurations very rarely seen in cells expressing wildtype MCAK (Andrews et al., 2004) . This directly phenocopies loss of Aurora B activity, implying MCAK is a key downstream effector of Aurora B. Subsequently, it has been shown that the inhibition of MCAK by the Aurora B complex is necessary for bipolar spindle formation around Xenopus chromatin (Gadea and Ruderman, 2004; Sampath et al., 2004) . Aurora B also regulates MCAK localization at the inner centromere (Andrews et al., 2004) as well as other kinetochore and spindle checkpoint proteins to kinetochores (MurataHori and Wang, 2002; Ditchfield et al., 2003) . Precisely how Aurora B-mediated modulation of MCAK activity and localization allows error correction to take place is still under investigation. PP1, located at the outer kinetochore (Trinkle-Mulcahy et al., 2003) , regulates Aurora B activity and dephosphorylates Aurora B substrates (Murnion et al., 2001) , leading us to postulate that dynamic cycles of phosphorylation and dephosphorylation locally modulating MCAK activity and localization may be key (Andrews et al., , 2004 . Whether the recently discovered inner-centromere protein ICIS (which immunoprecipitates with Aurora B, INCENP and MCAK), which appears to recruit MCAK to the inner-centromere and stimulate its microtubule-destabilizing activity in vitro (Ohi et al., 2003) , also contributes to the regulation in vivo remains an open question. The identification of MCAK as a bona fide, in vivo Aurora B substrate, whose functions closely match those of Aurora B, now places MCAK at centre stage. The detailed mechanism by which Aurora B regulates microtubule dynamics and microtubulekinetochore attachment will be critical to unravel if we are to target Aurora B and its downstream effectors in a therapeutic context. MCAK phosphorylation status and localization present themselves as attractive biomarkers for Aurora B inhibition. The Aurora B complex: new subunits and old debates Aurora B exists in a stable complex with INCENP and survivin, all behaving as chromosome passengers (Vagnarelli and Earnshaw, 2004) . INCENP and survivin have regulatory and targeting functions (see Andrews et al., 2003) . Both INCENP and survivin are phosphorylated by Aurora B in vitro (Knatko and Swedlow, unpublished; Kang et al., 2001; Cheeseman et al., 2002; Wheatley et al., 2004) .
Survivin
This essential subunit of the Aurora B complex has been hailed as a key inhibitor of apoptosis (see Altieri, 2003 , and references therein). Survivin levels are an often-used prognostic marker for cancer progression. A number of cancer therapies under development are based on reactivation or depletion of survivin Ning et al., 2004; Uchida et al., 2004) . However, survivin's proposed anti-apoptotic role is highly controversial. Indeed, recent studies have largely ruled out a direct anti-apoptotic role for survivin: in a recent study using Cre-Lox thymocytes lacking survivin, no evidence could be found for a direct role in apoptosis (although induction of p53 and p21, growth arrest and cell death were observed), leading the authors to postulate that survivin prevents 'mitotic catastrophe', rather than protects cells from apoptotic stimuli ; a second independent study came to similar conclusions (Xing et al., 2004) . Mitotic catastrophe has been partially characterized and appears to possess some of the classical features of apoptosis such as caspase-2 activation (Castedo et al., 2004) . A recent study using shRNA in both primary lung fibroblasts and normal epithelial cells revealed that cells could survive in the absence of survivin, but failed to segregated chromosomes or perform cytokinesis successfully, undergoing a p53-dependent block to re-replication (Yang et al., 2004a) . Two other reports also failed to find apoptotic defects in survivin RNAi HeLa cells (Carvalho et al., 2003; Lens et al., 2003) . In contrast, another study reports apoptotic cell death and strong suppression of tumour cell growth in a mouse xenograft model using adenovirus-mediated transfer of siRNA against survivin (Uchida et al., 2004) . Furthermore, one study recently pinpointed a single residue in survivin (Asp53) that affects survivin's anti-apoptotic function-mutation of this residue to alanine converted survivin into a p53-independent pro-apoptotic protein . It is difficult to ignore all the evidence that implicates survivin as an important anti-apoptotic factor. Perhaps it is the hypomorphic nature of shRNA/siRNA experiments and the potential for adaptation in Cre-Lox experiments which gives credence to the notion that apoptosis is not directly inhibited by survivin. Alternatively, given survivin's known function as part of the Aurora B complex, does lack of survivin perturb spindle checkpoint function to such an extent that it leads to mitotic catastrophe, which under certain conditions can be read as apoptosis? The importance of apoptotic versus non-apoptotic cell death pathways in cancer therapy is extremely important and has been reviewed elsewhere . The true nature of survivin's role in cell survival therefore remains the subject of much debate, but of critical importance in the cancer therapy arena.
Borealin
Recently, a fourth Aurora B complex subunit was described independently by two groups (Gassmann et al., 2004; Sampath et al., 2004) . This small conserved protein, called Borealin in human cells (Gassmann et al., 2004) , and Dasra B in Xenopus (Sampath et al., 2004) , immunoprecipitates with Aurora B, INCENP and survivin. Borealin is weakly related to CSC-1, a protein shown to be part of the Aurora B complex in Caenorhabditis elegans (Romano et al., 2003) . Borealin appears to specifically target the Aurora B complex to centromeres (Gassmann et al., 2004) . Borealin RNAi leads to biorientation defects -in particular a striking increase in merotelic and syntelic microtubule-kinetochore attachments -as well as multipolar spindles that form after biorientation and severely perturb anaphase chromosome segregation (Gassmann et al., 2004) . Borealin is an Aurora B substrate in vitro, but unlike INCENP and survivin does not stimulate Aurora B activity (Gassmann et al., 2004) . Significantly, in contrast to Aurora B RNAi, Borealin RNAi had little effect on histone H3 Ser 10 phosphorylation (Gassmann et al., 2004) . The implication of this result is that separate Aurora B subcomplexes exist with distinct substrate specificities, a potentially interesting avenue for future inhibitor design. Kinases and phosphatases have multiple substrates; therefore, complete inhibition of enzyme activity or loss of mRNA expression by RNAi is predicted to result in a more severe phenotypes than depletion of their associated targeting subunits or specialized regulators. It is for this reason that a complete picture of the makeup of the Aurora kinase complexes is necessary and desirable.
Aurora kinases and the spindle checkpoint
The spindle assembly checkpoint is a critical surveillance mechanism to ensure faithful chromosome segregation at the metaphase-anaphase transition. Defects in this checkpoint may cause the aneuploidy found in many cancer cells. The checkpoint monitors both the microtubule attachment status of the cells' kinetochores and the tension that develops across sister centromeres when chromosomes are fully bioriented. Only when all chromosomes are bioriented and at the metaphase plate is the checkpoint relieved and the cell cycle then allowed to advance (reviewed by Musacchio and Hardwick, 2002) . Spindle checkpoint defects generate a CIN phenotype and are linked to tumorigenesis (reviewed by Draviam et al., 2004; Lengauer and Wang, 2004) .
Aurora kinases have been implicated in the spindle checkpoint in yeast and metazoans. The single Aurora in Schizosacchromyses pombe, ark1, has been shown to function in the attachment arm of the checkpoint (Petersen and Hagan, 2003) . However, in budding yeast, Ipl1p may have a role in the tension arm of the checkpoint (Biggins and Murray, 2001 ). Aurora A may alter spindle checkpoint function in metazoans, since its overexpression leads to polyploidization in the presence of the chemotherapeutic agent paclitaxel, suggestive of an over-ride of the spindle checkpoint, an effect dependent on the BUB1 checkpoint gene (Anand et al., 2003) . In another study, Aurora A caused checkpoint override in nocodazole and disrupted the binding of BubR1 to Cdc20 leading to a CIN phenotype (Jiang et al., 2003) . Whether these result indicate a direct effect of Aurora A on spindle checkpoint function remains to be determined, since two other reports implicate Aurora B in the spindle checkpoint. Loss of Aurora B function caused a failure to retain checkpoint proteins at the kinetochore and led to an over-ride of only the taxol-sensitive, 'tension-sensing', arm of the spindle checkpoint (Ditchfield et al., 2003; Hauf et al., 2003) . These results mirror those observed when survivin is depleted by RNAi (Carvalho et al., 2003; Lens et al., 2003) and in the Ipl1 mutant in budding yeast (Biggins and Murray, 2001) . Given Aurora A's apparent role in Aurora B recruitment, the Aurora A's effects on the checkpoint may be indirect.
Of paramount importance is how Aurora kinase inhibition effects checkpoint function and cell cycle progression -the treatment of mammalian cells with Aurora inhibitors causes checkpoint over-ride, premature exit from mitosis during metaphase and cytokinesis failure, leading to polyploidization (Ditchfield et al., 2003; Hauf et al., 2003) , a situation not necessarily conducive to tumour killing. What lies at the heart of the matter here is the whether a cell maintains a checkpoint-triggered mitotic arrest, and whether the cell subsequently enters a cell death pathway or re-enters the cell cycle. The outcome seems to be determined by many factors such as the cause of the checkpoint arrest, its duration, the dose of the inhibitor, the cell type and genetic makeup (for an extensive review, see Rieder and Maiato, 2004) .
Aurora kinase inhibitors
Since the discovery of the Aurora kinases, much effort has been made by pharmaceutical companies to identify inhibitors. To date, three Aurora kinase inhibitors have been fully published (Ditchfield et al., 2003; Hauf et al., 2003; Harrington et al., 2004; see Table 1 ). In addition, a derivative of an original parent structure in the patent database has been synthesized and utilized in two studies (Straight et al., 2003; Lampson et al., 2004) , but no data exist on the specificity of this latter compound in vitro or in vivo.
ZM447439
ZM447439 (Ditchfield et al., 2003) is one of a number of compounds developed by AstraZeneca, generated by screening a 250 000 compound library using Aurora A kinase and a model peptide substrate. ZM447439 inhibits Aurora A and B, but is at least 10-fold more potent against Aurora kinases than against the other 13 kinases tested (see Table 1 ). ZM447439 caused growth inhibition in a colony-forming assay, a small increase in the level of apoptotic cells and p53-dependent polyploidization (see Table 1 ).
Hesperadin
Hesperadin (Hauf et al., 2003) was discovered by Boehringer Ingelheim by virtue of its effects on ploidy. Hesperadin specificity was tested against Aurora B (but not Aurora A) and a diverse panel of 25 kinases in vitro, seven of which were inhibited with reasonable K i s (see Table 1 ). It is unclear whether Hesperadin is a useful drug for therapeutics since it generated highly polyploid cells with no apparent loss of viability.
VX-680
VX-680 is the most recently published drug (Harrington et al., 2004) , coming out of a knowledge-based chemical synthesis programme undertaken by Vertex Pharmaceuticals, drawing on 'unique structural features' in Aurora A. VX-680 potently inhibited all three Aurora kinases but had greater than 100-fold selectivity for Auroras over a diverse panel of 55 kinases tested in vitro. The phenotypes associated with VX-680 treatment are summarized in Table 1 . Significantly, VX-680 is high effective in killing three different tumour cell types (leukemia, colon and pancreas) in xenograft models. VX-680 also potently killed treatment-refractory primary AML cells from patients. This efficacy was apparently achieved with some level of toxicity to bone-marrow cells, as the authors reported a degree of neutropenia and some loss in body weight, although these recovered after drug withdrawal. Unfortunately, no evidence was presented to indicate the presence or absence of other toxic side effects and/or long-term survival rates in treated mice, a necessary next step towards clinical trials. A key unanswered question is exactly how VX-680 leads to tumour cell death, since only a small proportion of cells were detectable apoptotic. As has been pointed out recently (Sausville, ), tumour growth rates in patients rarely match those of the rapidly growing xenograft tumours in model systems. A critical question, which applies to the use of all kinase inhibitors uses in oncology, is whether the efficacy of these ostensibly reversible Aurora kinase inhibitors, when administered over short periods, translates into clinically useful diminution in tumour growth in situ. It is noteworthy that the clinically highly effective taxanes bind to their target (tubulin) essentially irreversibly. Chemotherapeutic agents that target microtubules have been used effectively to kill cancer cells for over 35 years (reviewed by Mollinedo and Gajate, 2003) . The taxanes (e.g. paclitaxel/taxol), the epothilones and the discodermolides, all stabilize microtubules by inhibiting their dynamics and potently induce p53-independent apoptosis in cancer cells. The Vinca alkaloids (vincristine, vinblastine and vindestine), nocodazole and colchicine all destabilize microtubules, leading to cell cycle arrest and apoptosis. Many other naturally occurring antimitotic compounds also target tubulin (see Mollinedo and Gajate, 2003) . While these classes of therapeutic drug are effective, they do not appear to discriminate between dividing and nondividing cells -paclitaxel, for instance, causes peripheral neuropathy due to its effects on the neuronal microtubule network. The recent revelation that Aurora B in particular affects microtubule dynamics, spindle assembly and spindle checkpoint function is therefore of considerable interest in this context. We may be able to exploit these inter-relationships in order to produce new therapeutic reagents, to inform the design of treatment regimens (e.g. combination therapies) and thereby arrest mitotic cancer cells, triggering their death.
Anticancer targets for therapy
What makes a good target for cancer therapy? Ideally, the target, whether it is a specific gene, or protein, or process, would be different between the cancer cell and the normal cell. Defining differences between cancer cells and normal cells is a critical yet daunting challenge. Techniques as diverse as classical human genetics, microarrays (genome and proteome), cell biology and biochemistry are currently being used to pinpoint these differences. In the case of protein kinases as targets, it is important to differentiate between kinases proven to be pivotal in the cancer phenotype (e.g. mutationally activated) and other kinases that are might be peripherally involved (e.g. overexpressed in cancer cells) by non-specifically allowing deregulated cell growth and division. With the development of techniques to analyse the phosphoproteomes of cell populations, drug specificity questions may now be addressable in normal versus tumour cells, an approach complementary to potentially uninformative in vitro biochemical assays. Genetic variations between patients and between different cell populations within an individual's cancer, can influence drug efficacy and could represent considerable challenges to overcome for drug use in the future. The availability of a tailored panel of biomarkers will be essential to assess phenotypic changes when different inhibitors and combinations of inhibitors are used. Equally, an in-depth understanding of the molecular basis of genetic instability in tumours will be essential. Pharmaceutical companies indisputably have the resources to enable these types of large pharmacogenomic and proteomic studies, but will profit-led drug discovery take sufficient time to dissect the inter-relationships between signalling pathways? Indeed, there has been vocal criticism of the current modus operandi of pharmaled drug discovery (Dancey and Sausville, 2003; Sager and Lengauer, 2003) . So, do the Aurora kinases represent good cancer therapy targets? Aurora A overexpression is correlated with tumour progression. Aurora A is also mutated in certain cancers and behaves, at least in certain circumstances, as an oncogene. Aurora A's interaction with tumour suppressors such as p53, BRCA1 and lats2 is also suggestive of a real connection to oncogenesis. On the other hand, Aurora B is intimately involved in preventing CIN, a phenomenon frequently implicated in the genetic heterogeneity of cancers and may even drive oncogenesis. Survivin, part of the Aurora B complex, may well be a key protector against apoptosis and/or mitotic catastrophe. Given these facts, as well as their known roles in so many fundamentally important aspects of a range of cell cycle events (e.g. centrosome function, mitotic entry, spindle assembly, kinetochore function, chromosome segregation, microtubule dynamics, spindle checkpoint function and cytokinesis), pharmaceutical companies clearly believe Aurora kinases are hot property.
For clinicians, the demonstration that small molecule Aurora kinase inhibitors are effective at killing cancer cells has brought these kinases under the spotlight; however, it seems appropriate to voice a cautionary note as to the overall efficacy of such inhibitors in cancer treatment. Aurora inhibitors may trigger apoptosis in a proportion of cells and lead to the arrest of tumour growth in model systems, but it is noticeable that these inhibitor treatments only increased the proportion of apoptotic cells slightly. Nothing is known about how the inhibitors cause cell death (e.g. is it the result of polyploidization), to what extent this happens in vivo and whether the long-term outcome of their inhibition is favourable for maintaining a long-term remission. On face value, inhibition of any kinase required for stable chromosome inheritance is dangerous, because of a greater probability of genetic heterogeneity and hence the potential for tumour evolution. Undoubtedly, massive chromosome loss does, in the majority of cells, lead to cell death, but at what point does increased chromosome instability trigger cell death pathways? In addition, Aurora B is required for cytokinesis and its inhibition leads to polyploidization -a condition that may result in the survival of a severely aneuploidy cancerous cell. Nothing is understood of how this is sensed in the cell. More studies are required to ascertain the long-term effects of Aurora kinase inhibitor administration, in a suitable model organism. Rushing Aurora kinase inhibitors to the clinic would seem to be a rash move at this juncture. A more detailed understanding of the interplay between Aurora kinases, the microtubule cytoskeleton and apoptosis/mitotic catastrophe pathways will allow us to decide on strategies to treat cancer cells effectively and achieve the holy grail: an antimitotic drug that is tumour cell-specific and triggers cell death pathways.
Horizons
While much is known of Aurora A regulation, structure and its role in oncogenesis, little is understood about its key in vivo substrates and their cellular functions. Equally, while a great deal is understood about Aurora B's in vivo function, detailed knowledge of its regulation is only just emerging and structural knowledge is currently absent. Significantly, the structure of the Aurora B in complex with an INCENP fragment (7inhibitor) will soon be available in the public domain (Mussachio, A and Mapelli M, personal communication), which will go some way to redressing the balance, given the wealth of structural information on Aurora A.
If the Aurora kinases are bona fide targets for cancer therapy, an integrated molecular and cellular understanding of their function, interactions, dynamics, upstream regulators and downstream effectors in different cell types will be required to properly inform drug screening programmes and therapies. Many key questions remain unanswered. What signalling pathways activate the kinase activity of the Auroras in vivo? How does Aurora kinase structure and/or subunit composition dictate its localization and substrate specificity in vivo? Indeed, how many substrates are phosphorylated by each Aurora kinase in different cell types? To what extent do the Aurora kinase substrates overlap and what functional interactions exist between family members? What is the function of Aurora C? What are the molecular details underlying the connections between these kinases and the spindle and the spindle checkpoint and can we readily exploit these connections to kill tumour cells specifically? Of great interest would be to ascertain if mutations in genes encoding Aurora B complex components are associated with cancer.
A critical issue is how our knowledge of Aurora kinase structure and function will inform the strategies employed in the search for new anticancer therapeutics. In the case of small-molecule kinase inhibitors, will the key drugs come from 'blindly' screening compound libraries, be they the small natural compound libraries or the huge synthetic libraries? Will the structurecentric, 'knowledge-based' drug design strategy used commonly at present, generate useful selective inhibitors? Indeed, will ATP-competitive inhibitors in general be of sufficient selectivity and of high enough affinity to have efficacy in the context of a tumour, inside a patient? Adaptive mutations can and do arise in target proteins, leading to drug resistance -a clear problem in the treatment of certain cancers with tyrosine kinase inhibitors (Pao et al., 2005) . An alternative school of thought advocates the use of either less selective, kinase family-specific inhibitors or cocktails of drugs, to deliver the lethal blow to the cancer. An area somewhat in its infancy is to screen for compounds that disrupt proteinprotein interactions (reviewed by Pagliaro et al., 2004) , rather than against the active site. Small-molecule inhibitors remain the vogue; other reagents such as cell-permeant peptides have had technical limitations. Cell permeability, bioavailability, catabolic rate, offtarget toxicity and drug resistance are still critical issues in the use of drugs in cancer therapy.
RNAi-based therapeutics could have an important role to play in the fight against cancer. In this context, RNAi of Aurora kinases' downstream effectors or targeting subunits or specific splice variants, if applicable, may allow the highly selective targeting of a defined subset of kinase functions. The drawback of using RNAi is its hypomorphic nature, the potential for cell adaptation and the possibility of an off-target effect. An alternative to RNAi is the use of gene therapy using viral delivery of dominant-negative mutants -an approach employed recently using a pro-apoptotic allele of survivin in the treatment of colon cancer (Tu et al., 2005) .
An emerging theme in the Aurora kinase field is that the phosphorylation status of a target protein determines its location. Therefore, a clearly important future strategy will be to use cell-based screens, tailored to monitor loss of specific Aurora functions (e.g. screening using panels of phospho-specific antibodies and/or using substrate localization as readouts). This may work alongside, or even supercede, conventional biochemical high-throughput screens.
With all the new data emerging on Aurora kinases, the great excitement in the field is probably justified. Hopefully, the Aurora kinases will prove to be genuinely bright lights on the therapeutic horizon and not just a case of now you see them now you don't.
